SEM Herman, RZ Mustafa, J Jones, DH Wong… - Clinical Cancer …, 2015 - AACR
Purpose: Ibrutinib leads to a transient lymphocytosis in patients with chronic lymphocytic
leukemia (CLL) that develops within hours of starting drug and is due to the efflux of cells …